Report error Found 41  Enz. Inhib. hit(s) with all data for entry = 50012514  
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of [3H]Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of [3H]Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of [3H]Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of [3H]Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 15nMAssay Description:Inhibition of [3H]Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 19nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 24nMAssay Description:Inhibition of [3H]Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 24nMAssay Description:Inhibition of [3H]Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 26nMAssay Description:Inhibition of [3H]Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 28nMAssay Description:Inhibition of [3H]Arg-vasopressin binding to recombinant human vasopressin V2 receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 30nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 35nMAssay Description:Inhibition of [3H]Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 35nMAssay Description:Inhibition of [3H]Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 59nMAssay Description:Inhibition of [3H]Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 68nMAssay Description:Inhibition of [3H]Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 72nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 150nMAssay Description:Inhibition of [3H]Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 250nMAssay Description:Inhibition of [3H]Arg-vasopressin binding to recombinant human vasopressin V1a receptorMore data for this Ligand-Target Pair
TargetCytochrome P450 2C9(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataIC50: 7.40E+3nMAssay Description:Inhibition of cytochrome P450 2C9More data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataKi:  9nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataKi:  9nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataKi:  13nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataKi:  23nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataKi:  30nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataKi:  32nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataKi:  40nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataKi:  90nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataKi:  130nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataKi:  130nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataKi:  160nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataKi:  180nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataKi:  520nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V2 receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataKi:  620nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataKi:  890nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Human)
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Johnson and Johnson Pharmaceutical Research and Development
Curated by ChEMBL
Affinity DataKi:  2.60E+3nMAssay Description:Inhibition of AVP mediated activation of human vasopressin V1a receptor expressed in HEK293 cellsMore data for this Ligand-Target Pair
 
 	












